CMH Institute of Medical Sciences
Multan, Punjab Province, 66000, Pakistan
NCT Number: NCT07729189
This randomized controlled trial evaluated whether a single drop of 0.5% timolol maleate, administered before neodymium-doped yttrium aluminium garnet (Nd:YAG) laser posterior capsulotomy, reduced the rise in intraocular pressure compared with standard care alone. The study included adults aged 18-65 years who had developed posterior capsular opacification at least 3 months after cataract surgery and were scheduled to undergo Nd:YAG laser posterior capsulotomy. Participants were randomly assigned to receive either prophylactic topical timolol maleate or standard care without prophylactic timolol. Intraocular pressure was measured before the laser procedure and again 1 hour after the procedure by an ophthalmologist who was unaware of the assigned treatment. The study was based on the hypothesis that mean intraocular pressure 1 hour after posterior capsulotomy would be lower among participants who received prophylactic timolol maleate than among those who received standard care alone.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Multan, Punjab Province, 66000, Pakistan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One drop of 0.5% timolol maleate ophthalmic solution was administered topically immediately before Nd:YAG laser posterior capsulotomy.
No prophylactic intraocular pressure-lowering medication was administered before Nd:YAG laser posterior capsulotomy.
Time frame: 1 hour after Nd:YAG laser posterior capsulotomy
Intraocular pressure was measured in millimetres of mercury using a Canon non-contact tonometer. The mean intraocular pressure measured 1 hour after Nd:YAG laser posterior capsulotomy was compared between participants who received one drop of 0.5% topical timolol maleate before the procedure and participants who received standard care without prophylactic timolol.
CMH Multan Institute of Medical Sciences
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01732484
Capsule Opacification, Cataract
View Trial DetailsNCT01742910
Capsule Opacification, Cataract
Vienna, Austria
View Trial DetailsNCT03891446
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT02710916
Eye Diseases, Glaucoma
Bordeaux, Aquitaine, France
View Trial Details